Kitano, Shigehisa http://orcid.org/0000-0002-4041-8298
Fujiwara, Yutaka
Shimizu, Toshio
Iwasa, Satoru
Yonemori, Kan
Kondo, Shunsuke
Shimomura, Akihiko
Koyama, Takafumi
Ebata, Takahiro
Ikezawa, Hiroki
Hayata, Nozomi
Minoshima, Yukinori
Miura, Takuma
Kubota, Tomoki
Yamamoto, Noboru
Clinical trials referenced in this document:
Documents that mention this clinical trial
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
https://doi.org/10.1007/s00280-022-04480-w
Funding for this research was provided by:
Eisai Inc., Nutley, NJ, USA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 26 January 2022
Accepted: 27 September 2022
First Online: 26 October 2022
Declarations
:
: Shigehisa Kitano reports remuneration from ImmuniT Research Inc; honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Astra Zeneca, Chugai, MSD, and Pfizer; and research funds from Eisai, REGENERON, Boehringer Ingelheim, Astellas Pharma, Gilead Sciences, Daiichi Sankyo, Takara Bio, Ono Pharmaceutical, PACT Pharma, Chugai, and MSD. Yutaka Fujiwara reports research funding from Bristol-Myers Squibb and Chugai; and honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Novartis, ONO Pharmaceutical, Otsuka Pharmaceutical, and Pfizer, outside the submitted work. Toshio Shimizu reports research funds from Novartis, Eli Lilly, Daiichi-Sankyo, Bristol Myers Squibb, AbbVie, Eisai, AstraZeneca, Takeda Oncology, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Pfizer, Five Prime and Astellas Pharma. Satoru Iwasa has nothing to disclose. Kan Yonemori reports lecture fees from Eisai, Taiho, Pfizer, Eli Lilly, AstraZeneca, Takeda, Fuji Film, and Chugai; is an advisor for Takeda, Eisai, Novartis, Chugai, Ono, and AstraZeneca; has received grants for clinical trials from MSD, Daiichi-Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, and Nihon Kayaku. Shunsuke Kondo has nothing to disclose. Akihiko Shimomura reports honoraria from Chugai Pharmaceutical and Eli-Lilly Japan, and research funds from Chugai Pharmaceutical, AstraZeneca, Daiichi Sankyo, and Taiho Pharmaceutical. Takafumi Koyama reports honoraria from Sysmex. Takahiro Ebata has nothing to disclose. Hiroki Ikezawa is an employee of Eisai Co., Ltd. Nozomi Hayata is an employee of Eisai Co., Ltd. Yukinori Minoshima is an employee of Eisai Co., Ltd. Tomoki Kubota is an employee of Eisai Co., Ltd. Takuma Miura is an employee of Eisai Co., Ltd. Noboru Yamamoto reports honoraria from Chugai, Pfizer and Sysmex; and research funds from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, and Genmab.
: The study protocol was approved by relevant institutional review boards and conducted in accordance with the principles of the World Medical Association Declaration of Helsinki and Japan’s Good Clinical Practice. The protocol, informed consent form, and appropriate related documents were reviewed by the Institutional Review Board of National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.